Evidence-based management of pregnant women with sickle cell disease in high-income countries
- PMID: 36485166
- PMCID: PMC9820817
- DOI: 10.1182/hematology.2022000378
Evidence-based management of pregnant women with sickle cell disease in high-income countries
Abstract
Globally, patients living with sickle cell disease are now surviving to reproductive age, with life expectancy approaching 50 years in most countries. Thus, reproductive options are now essential for patients living with the condition. However, it can be associated with maternal, delivery, and fetal complications. Outcomes may vary depending on the level of expertise and resources. In this piece we provide an optional guideline for managing sickle cell disease in pregnancy. The therapeutic option of serial exchange prophylactic transfusion has been offered in the context of a clinical trial (TAPS2).
Copyright © 2022 by The American Society of Hematology.
Conflict of interest statement
Eugene Oteng-Ntim: no competing financial interests to declare.
Panicos Shangaris: no competing financial interests to declare.
References
-
- Royal College of Obstetricians and Gynaecologists. Management of sickle cell disease in pregnancy. Accessed 8 September 2022. https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guideline....
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
